Prestatyn, United Kingdom

Chris Ward

This inventor holds 25 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Sanofi-A Ventis Deutschland Gmbh, Nerudia Limited, Applied Research Associates, Inc.. Active years: 2014-2023.

USPTO Granted Patents = 25 

% Patents Active = 72.0

 

 

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 317(Granted Patents)


Location History:

  • Denbighshire, GB (2014 - 2018)
  • Dennbigshire, GB (2019 - 2020)
  • Denbigshire, GB (2020)
  • Prestatyn, GB (2016 - 2021)
  • Prestatyn Dennbigshire, GB (2019 - 2022)
  • St. Asaph, GB (2020 - 2023)

Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
Loading Chart...
25 patents (USPTO):Explore Patents

Title: The Innovative Journey of Chris Ward

Introduction: Chris Ward, a talented inventor hailing from Prestatyn, GB, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Chris Ward's latest patents include cutting-edge designs in the field of renewable energy, with a focus on solar power optimization and energy storage solutions.

Career Highlights: Throughout his illustrious career, Chris Ward has been recognized for his innovative spirit and problem-solving abilities. His inventions have revolutionized various industries, from sustainable energy to healthcare technology.

Collaborations: Chris Ward has collaborated with leading research institutions and universities to further develop his inventions. His partnerships with top companies have led to the successful commercialization of his patented technologies.

Conclusion: In conclusion, Chris Ward stands as a beacon of innovation in the world of inventors. His dedication to creating solutions that positively impact society showcases his passion for pushing the boundaries of what is possible in the realm of technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…